Lucilia Pharma

Mae Lucilia Pharma yn gwmni darganfod cyffuriau sy’n canolbwyntio ar fanteisio ar briodweddau moleciwlaidd buddiol endidau sy’n cael eu hysgarthu/eu secretu gan gynrhon gwahanol rywogaethau o bryfed (gan gynnwys Lucilia sericata) sydd eisoes yn cael eu defnyddio’n helaeth yn feddygol mewn therapi digramennu â chynrhon (MDT) i drin clwyfau cronig, megis briwiau diabetig ar goesau ac yn cynnwys pobl sydd wedi’u heintio â bacteria sy’n gwrthsefyll cyffuriau, gan gynnwys MRSA.

Defnyddir cynrhon yn rheolaidd yn glinigol ar gyfer trin clwyfau, yn enwedig lle mae trafferth cael y clwyfau i wella. Mae eu nodweddion gwrthficrobaidd yn adnabyddus iawn, er nad oes gwybodaeth gennym am y cyfansoddion gweithredol sy’n hwyluso iachau. Mae cynrhon wedi bod yma ers dros 60 miliwn o flynyddoedd ac nid yw bacteria wedi datblygu mecanwaith amddiffyn eto, felly gallai arunigo, adnabod a chreu cyfansoddyn gweithredol arwain at greu cyffur na fydd yn cael ei effeithio gan yr ymwrthedd gwrthfacteria sydd mor gyffredin heddiw.

The research at Swansea University underpinning Lucilia Pharma has already received funding from the Welsh Assembly Government's Academia for Business (A4B) programme to isolate and identify the anti-bacterial properties of these compounds in maggot secretions. Very high potency, small molecular weight compounds have been identified in very low concentrations with distinctive mechanisms of action suggesting interference in bacterial replication (and hence their inability to evolve defence mechanisms). Informed by this, Lucilia Pharma is also working with researchers from Bath University to look at FtsZ inhibitors which also disrupt bacterial growth and which again can be used to control bacterial infections.
Lucilla Pharma's mission is to bring a suite of products to market that overcome antimicrobial resistance and which can be used to stop e.g. MRSA outbreaks. It offers the promise of a completely new class of drug with a similar effect on healthcare that was attributed to penicillin in the 1930’s.

Back

Back to Top